Clinical Trial: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282600) titled 'A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes' on Dec. 05.

Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Overweight Obesity

Intervention: DRUG: Eloralintide

Administered SC

DRUG: Placebo

Administered SC

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company

Disclaimer: Cu...